Triptorelin Trial NCT03678025 Status Update: Phase 3 Still Recruiting

On October 8, 2026, the clinical trial registry listed an update for a Phase 3 study involving triptorelin. The trial is titled "Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer." Its identifier is NCT03678025. The study status is recorded as recruiting. This trial is being conducted in the Phase 3 stage of clinical development. The update reflects the trial's current recruitment status as of the date listed. No results or outcome data were included in this status update. The trial explores standard systemic therapy with or without additional definitive treatment in participants with metastatic prostate cancer. Triptorelin's regulatory status remains approved. This brief reports only the recruitment status and trial details as provided in the registry entry. No efficacy or safety conclusions can be drawn from a recruitment status update. Readers interested in the broader context of triptorelin, including its approved uses and regulatory history, can consult the compound overview for additional background.